adagrasib, escitalopram.Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
alfentanil, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of amiodarone by QTc interval. Avoid or Use Alternate Drug.
amisulpride and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
escitalopram and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug.escitalopram increases toxicity of amitriptyline by QTc interval. Avoid or Use Alternate Drug.
escitalopram and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
apalutamide will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.apalutamide will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
escitalopram increases toxicity of arsenic trioxide by QTc interval. Avoid or Use Alternate Drug.
artemether and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of artemether/lumefantrine by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of asenapine by QTc interval. Avoid or Use Alternate Drug.
asenapine transdermal and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of azithromycin by QTc interval. Avoid or Use Alternate Drug.
buprenorphine and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
buprenorphine buccal and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
buprenorphine subdermal implant and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
buprenorphine transdermal and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
buprenorphine, long-acting injection and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible.
escitalopram and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
ceritinib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.ceritinib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
escitalopram increases toxicity of chlorpromazine by QTc interval. Avoid or Use Alternate Drug.
citalopram and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
clarithromycin, escitalopram.Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. To monitor for the prolongation of QT/QTc and/or development of ventricular tachyarrhythmias the labeling recommends monitoring QT interval or ECG.escitalopram increases toxicity of clarithromycin by QTc interval. Avoid or Use Alternate Drug.clarithromycin will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
escitalopram and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of crizotinib by QTc interval. Avoid or Use Alternate Drug.
escitalopram and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
desflurane and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of disopyramide by QTc interval. Avoid or Use Alternate Drug.
dofetilide increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug.escitalopram increases toxicity of dofetilide by QTc interval. Avoid or Use Alternate Drug.
escitalopram and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of encorafenib by QTc interval. Avoid or Use Alternate Drug.
escitalopram and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
enzalutamide will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
escitalopram increases toxicity of eribulin by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of erythromycin base by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of erythromycin ethylsuccinate by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of erythromycin lactobionate by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of erythromycin stearate by QTc interval. Avoid or Use Alternate Drug.
fentanyl, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
fentanyl intranasal, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
fentanyl transdermal, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
fentanyl transmucosal, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
fexinidazole and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fexinidazole will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.
escitalopram increases toxicity of flecainide by QTc interval. Avoid or Use Alternate Drug.
fluoxetine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.escitalopram and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug.
fluvoxamine and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of foscarnet by QTc interval. Avoid or Use Alternate Drug.
gilteritinib will decrease the level or effect of escitalopram by Other (see comment). Avoid or Use Alternate Drug. Coadministration of gilteritinib with drugs that inhibit 5HT2B or sigma nonspecific receptors. Avoid use of these drugs with gilteritinib unless coadministration is necessary.gilteritinib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.
escitalopram and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
granisetron, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
histrelin increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
hydromorphone, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
hydroxychloroquine sulfate and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.escitalopram increases toxicity of hydroxychloroquine sulfate by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of ibutilide by QTc interval. Avoid or Use Alternate Drug.
idelalisib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates
escitalopram increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug.
escitalopram and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of inotuzumab by QTc interval. Avoid or Use Alternate Drug.
isoflurane and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
ivosidenib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ivosidenib will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
escitalopram and levomilnacipran both increase serotonin levels. Avoid or Use Alternate Drug.
linezolid and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
escitalopram and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.
lonafarnib will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.
escitalopram increases toxicity of lopinavir by QTc interval. Avoid or Use Alternate Drug.
escitalopram and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.
macimorelin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
escitalopram and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.
mefloquine increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
escitalopram and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.meperidine, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of methadone by QTc interval. Avoid or Use Alternate Drug.
methylene blue and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.
metoclopramide and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactions
escitalopram, metoclopramide intranasal.Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
escitalopram and milnacipran both increase serotonin levels. Avoid or Use Alternate Drug.
mirtazapine and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
mobocertinib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
morphine, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram and nefazodone both increase serotonin levels. Avoid or Use Alternate Drug.nefazodone will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
netupitant/palonosetron, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of nilotinib by QTc interval. Avoid or Use Alternate Drug.
escitalopram and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychom*otor performance and cause daytime impairment.
escitalopram and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.ondansetron, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of osimertinib by QTc interval. Avoid or Use Alternate Drug.
oxaliplatin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
ozanimod increases toxicity of escitalopram by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
escitalopram increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug.
palonosetron, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
escitalopram and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
escitalopram and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of pazopanib by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of pentamidine by QTc interval. Avoid or Use Alternate Drug.
escitalopram, phentermine.Either increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome.
escitalopram increases toxicity of pimavanserin by QTc interval. Avoid or Use Alternate Drug.
escitalopram and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of procainamide by QTc interval. Avoid or Use Alternate Drug.
escitalopram and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of quinidine by QTc interval. Avoid or Use Alternate Drug.
rasagiline and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
remifentanil, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
ribociclib increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug.escitalopram increases toxicity of ribociclib by QTc interval. Avoid or Use Alternate Drug.
ropeginterferon alfa 2b, escitalopram.Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.
escitalopram increases toxicity of saquinavir by QTc interval. Avoid or Use Alternate Drug.saquinavir will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
selegiline transdermal and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug.
selinexor, escitalopram. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
escitalopram and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.escitalopram increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug.
sevoflurane and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
siponimod and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of sorafenib by QTc interval. Avoid or Use Alternate Drug.
escitalopram and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
escitalopram and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.
sufentanil, escitalopram.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
tedizolid, escitalopram.Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.
escitalopram increases toxicity of tetrabenazine by QTc interval. Avoid or Use Alternate Drug.
escitalopram increases toxicity of toremifene by QTc interval. Avoid or Use Alternate Drug.
escitalopram and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.
triptorelin increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
tucatinib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.
escitalopram increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
escitalopram, vandetanib.Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
vemurafenib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.escitalopram increases toxicity of vemurafenib by QTc interval. Avoid or Use Alternate Drug.
escitalopram and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
escitalopram increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
escitalopram, vilazodone.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .
escitalopram, vortioxetine.Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.
voxelotor will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
escitalopram, zuranolone.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of zuranolone with other CNS depressants may increase impairment of psychom*otor performance or CNS depressant effects. If unavoidable, consider dose reduction. .
escitalopram and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram, aceclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, acemetacin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
albuterol and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and escitalopram both increase QTc interval. Use Caution/Monitor.
almotriptan, escitalopram.Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely. Exercise caution when concomitantly using agents that enhance serotonin activity. Monitor for the development of serotonin toxicity/serotonin syndrome during such therapy.
escitalopram increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
amobarbital will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.
escitalopram and amphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
anagrelide and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram increases effects of apixaban by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.
escitalopram increases toxicity of apomorphine by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
aripiprazole and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram, aspirin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, aspirin rectal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, aspirin/citric acid/sodium bicarbonate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
atazanavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased risk of serotonin syndrome.
escitalopram increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and escitalopram both increase QTc interval. Use Caution/Monitor.
azithromycin increases toxicity of escitalopram by QTc interval. Use Caution/Monitor.
escitalopram and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
belzutifan will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information.
benzhydrocodone/acetaminophen, escitalopram.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
escitalopram, betrixaban.Either increases levels of the other by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.
escitalopram, buprenorphine subdermal implant.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
escitalopram, buprenorphine, long-acting injection.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
butabarbital will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
butalbital will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
cannabidiol will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol.
carbamazepine will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram, celecoxib.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
cenobamate will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cenobamate will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate. cenobamate, escitalopram.Either increases effects of the other by sedation. Use Caution/Monitor.
chloramphenicol will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
chloroquine increases toxicity of escitalopram by QTc interval. Use Caution/Monitor.
escitalopram, choline magnesium trisalicylate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram increases toxicity of ciprofloxacin by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of clofazimine by QTc interval. Modify Therapy/Monitor Closely.
escitalopram increases toxicity of clomipramine by QTc interval. Use Caution/Monitor.
clonidine, escitalopram.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.
escitalopram increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration of SSRIs with clopidogrel may increase the risk of bleeding.
escitalopram increases levels of clozapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .escitalopram increases toxicity of clozapine by QTc interval. Use Caution/Monitor.
cobicistat will increase the level or effect of escitalopram by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with SSRIs and cobicistat. cobicistat will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.
crizotinib increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crizotinib and escitalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
cyproheptadine decreases effects of escitalopram by pharmacodynamic antagonism. Use Caution/Monitor. Cyproheptadine may diminish the serotonergic effect of SSRIs.
dabrafenib will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
escitalopram and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychom*otor performance and cause daytime impairment.
escitalopram increases toxicity of dasatinib by QTc interval. Use Caution/Monitor.
defibrotide increases effects of escitalopram by Other (see comment). Use Caution/Monitor. Comment: Defibrotide may enhance effects of platelet inhibitors.
escitalopram increases toxicity of degarelix by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of desipramine by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of deutetrabenazine by QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circ*mstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
escitalopram and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
dexmethylphenidate increases effects of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram, dextroamphetamine transdermal.Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).
diazepam buccal, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
diazepam intranasal, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
dichlorphenamide, escitalopram. sedation. Use Caution/Monitor.
escitalopram, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
difelikefalin and escitalopram both increase sedation. Use Caution/Monitor.
escitalopram, diflunisal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.
dolasetron, escitalopram.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor ECG, symptoms of serotonin syndrome especially during initiation/titration.escitalopram increases toxicity of dolasetron by QTc interval. Use Caution/Monitor.
donepezil and escitalopram both increase QTc interval. Use Caution/Monitor.
duloxetine and escitalopram both increase serotonin levels. Use Caution/Monitor.
duvelisib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.
escitalopram increases effects of edoxaban by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.
efavirenz will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.efavirenz will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.efavirenz and escitalopram both increase QTc interval. Use Caution/Monitor.
elagolix will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.elagolix will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
eletriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
eliglustat and escitalopram both increase QTc interval. Use Caution/Monitor.
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
encorafenib, escitalopram. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
escitalopram and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
eslicarbazepine acetate will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
esomeprazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
escitalopram, etodolac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
etravirine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.etravirine will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
ezogabine, escitalopram.Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.escitalopram increases toxicity of ezogabine by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed, particularly when dose titrated to 1200mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
fedratinib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fedratinib will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.
felbamate will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
escitalopram, fenbufen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, escitalopram.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.
escitalopram, fenoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
fexinidazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
fingolimod and escitalopram both increase QTc interval. Use Caution/Monitor.
fish oil triglycerides will increase the level or effect of escitalopram by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants.
fluconazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.escitalopram increases toxicity of fluconazole by QTc interval. Use Caution/Monitor.
escitalopram and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
escitalopram increases toxicity of fluphenazine by QTc interval. Use Caution/Monitor.
escitalopram, flurbiprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram increases effects of fondaparinux by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.
escitalopram increases toxicity of formoterol by QTc interval. Use Caution/Monitor.
fosamprenavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.
fosphenytoin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
frovatriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
gabapentin, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
gabapentin enacarbil, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
gadobenate and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram and ganaxolone both increase sedation. Use Caution/Monitor.
escitalopram increases toxicity of gemifloxacin by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of gemtuzumab by QTc interval. Use Caution/Monitor.
gepirone and escitalopram both increase QTc interval. Modify Therapy/Monitor Closely.gepirone and escitalopram both increase serotonin levels. Use Caution/Monitor. Monitor for symptoms of serotonin syndrome when gepirone is used gepirone with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinue gepirone and/or concomitant serotonergic drug.
granisetron and escitalopram both increase QTc interval. Use Caution/Monitor.
green tea, escitalopram. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.
haloperidol and escitalopram both increase QTc interval. Use Caution/Monitor.escitalopram increases toxicity of haloperidol by QTc interval. Use Caution/Monitor.
hydrocodone, escitalopram.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
escitalopram, hydroxyurea. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of myelosuppression.
hydroxyzine and escitalopram both increase QTc interval. Use Caution/Monitor.
ibrutinib will increase the level or effect of escitalopram by anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding.
escitalopram, ibuprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, ibuprofen IV.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
icosapent, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time. Periodically monitor if coadministered with other drugs that affect bleeding.
iloperidone increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
indacaterol, inhaled, escitalopram. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.escitalopram increases toxicity of indacaterol, inhaled by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of indapamide by QTc interval. Use Caution/Monitor.
indinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.
escitalopram, indomethacin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.
isoniazid will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.escitalopram and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram increases toxicity of isradipine by QTc interval. Use Caution/Monitor.
istradefylline will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
itraconazole will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.itraconazole and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, ketorolac intranasal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.
lamotrigine increases toxicity of escitalopram by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychom*otor impairment may be enhanced.
escitalopram increases toxicity of lapatinib by QTc interval. Use Caution/Monitor.
lasmiditan, escitalopram.Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.escitalopram increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.
lemborexant, escitalopram.Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
lenacapavir will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
escitalopram and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
escitalopram increases toxicity of levofloxacin by QTc interval. Use Caution/Monitor.
escitalopram, lisdexamfetamine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).
escitalopram and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and escitalopram both increase QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of lofexidine by QTc interval. Use Caution/Monitor.
lopinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotinin syndrome.
lorlatinib will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram, lornoxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
lumacaftor/ivacaftor, escitalopram. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .lumacaftor/ivacaftor will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. A higher dose of escitalopram may be required to obtain desired therapeutic effect. Escitalopram is a CYP3A and CYP2C19 substrate. Lumacaftor/ivacaftor is a strong inducer of CYP3A and has the potential to induce CYP2C19.
lurasidone, escitalopram.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
escitalopram increases toxicity of maprotiline by QTc interval. Use Caution/Monitor.
mavorixafor and escitalopram both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.
escitalopram, meclofenamate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, mefenamic acid.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram increases toxicity of mefloquine by QTc interval. Use Caution/Monitor.
escitalopram, meloxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor.
methylphenidate transdermal will increase the level or effect of escitalopram by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.
midazolam intranasal, escitalopram.Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
mifepristone, escitalopram. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.mifepristone will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.escitalopram increases toxicity of mifepristone by QTc interval. Use Caution/Monitor.
escitalopram and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.
mitotane decreases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
modafinil will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely.
escitalopram and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram and moxifloxacin both increase QTc interval. Modify Therapy/Monitor Closely.moxifloxacin and escitalopram both increase QTc interval. Modify Therapy/Monitor Closely.
escitalopram, nabumetone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
nafcillin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram, naproxen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
naratriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
nelfinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.
escitalopram increases toxicity of nortriptyline by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of octreotide by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of olanzapine by QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances.
escitalopram, olanzapine/samidorphan.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of diazepam, alcohol, or other CNS acting drugs may potentiate orthostatic hypotension observed with olanzapine. Additive sedation may also occur.
escitalopram, oliceridine.Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely.
escitalopram and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
omeprazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
osilodrostat and escitalopram both increase QTc interval. Use Caution/Monitor.escitalopram and osilodrostat both increase QTc interval. Use Caution/Monitor. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval
osimertinib and escitalopram both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
oxaliplatin will increase the level or effect of escitalopram by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
escitalopram, oxaprozin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
oxcarbazepine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
oxycodone increases effects of escitalopram by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.
ozanimod and escitalopram both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
escitalopram, parecoxib.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
escitalopram and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.
pentobarbital will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
escitalopram increases toxicity of perphenazine by QTc interval. Use Caution/Monitor.
phenobarbital will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.phenobarbital will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
phenytoin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram, piroxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram increases toxicity of posaconazole by QTc interval. Use Caution/Monitor.posaconazole will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pregabalin, escitalopram.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
primaquine and escitalopram both increase QTc interval. Use Caution/Monitor.
primidone will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.primidone will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of protriptyline by QTc interval. Use Caution/Monitor.
quetiapine, escitalopram.Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
escitalopram and quinine both increase QTc interval. Use Caution/Monitor.
quizartinib, escitalopram.Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
escitalopram increases toxicity of ranolazine by QTc interval. Use Caution/Monitor.
remimazolam, escitalopram.Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
ribociclib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
rifabutin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
rifampin will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.rifampin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
rifapentine will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
rilpivirine increases toxicity of escitalopram by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.escitalopram increases toxicity of rilpivirine by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of risperidone by QTc interval. Use Caution/Monitor.
ritonavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.
escitalopram increases effects of rivaroxaban by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.
rizatriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram increases toxicity of romidepsin by QTc interval. Use Caution/Monitor.
escitalopram, safinamide.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor patients for symptoms of serotonin syndrome if SSRIs are coadministered with safinamide.
escitalopram, salicylates (non-asa).Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, salsalate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
secobarbital will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.secobarbital will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
selpercatinib increases toxicity of escitalopram by QTc interval. Use Caution/Monitor.
serdexmethylphenidate/dexmethylphenidate increases effects of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
sodium sulfate/?magnesium sulfate/potassium chloride increases effects of escitalopram by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using bowel preps together with drugs that lower the seizure threshold.
escitalopram, sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.
sodium sulfate/potassium sulfate/magnesium sulfate increases effects of escitalopram by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using bowel preps together with drugs that lower the seizure threshold.
escitalopram increases toxicity of solifenacin by QTc interval. Use Caution/Monitor.
sorafenib and escitalopram both increase QTc interval. Use Caution/Monitor.
sparsentan will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates.
stiripentol will decrease the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.
sufentanil SL, escitalopram.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
escitalopram, sulfasalazine.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, sulindac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
sumatriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
sumatriptan intranasal and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
escitalopram increases toxicity of sunitinib by QTc interval. Use Caution/Monitor.
escitalopram increases toxicity of tacrolimus by QTc interval. Use Caution/Monitor.
escitalopram and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.
tazemetostat will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
tecovirimat will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.tecovirimat will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
escitalopram increases toxicity of telavancin by QTc interval. Use Caution/Monitor.
tipranavir will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
tizanidine increases toxicity of escitalopram by pharmacodynamic synergism. Use Caution/Monitor. CNS depressants may enhance the psychom*otor impairment of escitalopram.
escitalopram, tolfenamic acid.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
escitalopram and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.
triclabendazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.
escitalopram increases toxicity of trimipramine by QTc interval. Use Caution/Monitor.
valbenazine and escitalopram both increase QTc interval. Use Caution/Monitor.
valerian and escitalopram both increase sedation. Use Caution/Monitor.
escitalopram increases toxicity of vardenafil by QTc interval. Use Caution/Monitor.
voclosporin, escitalopram.Either increases effects of the other by QTc interval. Use Caution/Monitor.
escitalopram, vorapaxar.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .
voriconazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.escitalopram increases toxicity of voriconazole by QTc interval. Use Caution/Monitor.voriconazole will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
escitalopram increases toxicity of vorinostat by QTc interval. Use Caution/Monitor.
escitalopram, warfarin.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serotonin release by platelets plays an important role in hemostasis. SSRIs and SNRIs may increase anticoagulation effect of warfarin. .
escitalopram, zanubrutinib.Either increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk.
zolmitriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.
